IMR Press / JOMH / Volume 15 / Issue 3 / DOI: 10.22374/jomh.v15i3.156

Journal of Men’s Health (JOMH) is published by IMR Press from Volume 17 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Dougmar Publishing Group.

Open Access Original Research

RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BENZOCAINE WIPES IN SUBJECTS WITH PREMATURE EJACULATION

Show Less
1 SBH Health System, Weill-Cornell Medical School and CUNY School of Medicine, New York, NY, USA
2 Department of Psychiatry, Weill-Cornell Medical College, New York, NY, USA
3 Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA
4 Albert Einstein College of Medicine, New York, NY, USA
5 Manhattan Medical Research, New York, NY, USA
J. Mens. Health 2019, 15(3), 80–88; https://doi.org/10.22374/jomh.v15i3.156
Submitted: 24 June 2019 | Accepted: 28 October 2019 | Published: 31 October 2019
Abstract

Aim

This study investigated the efficacy and safety of benzocaine wipes (PREBOOST) applied to the penis prior to intercourse for the treatment of men with premature ejaculation.

Materials and methods

The study utilized the local anesthetic benzocaine, in the form of wipes, for topical application to the glans penis prior to sexual intercourse. The design included three phases: screening and baseline, blinded randomized controlled, and an open-label phase with crossover of the placebo group to open-label active treatment. The two co-primary efficacy measures were the intravaginal ejaculatory latency time (IELT) measured by stopwatch, and the patient-reported outcome measured by the Index of Premature Ejaculation (IPE). Additional efficacy evaluation included a responder analysis using a predetermined 120s improvement in IELT as a responder threshold. Safety evaluation included patient-reported events along with a physical examination.

Results

The treatment phase showed a statistically significant increase from the baseline, in the treatment group (mean 165s) compared with the placebo group (mean 110s), P<0.007. After the second month of use, the treatment group had a mean IELT of 329.70s (±21.37 SE) in comparison to the placebo group which had a mean IELT of 110.10s (±9.90 SE) (P=0.001). The open-label phase showed further increase in IELT in the treatment group and a statistically significant increase in IELT in the placebo/crossover group. Using the IPE, the men in the treatment group reported significantly higher sexual satisfaction (P=0.047) and greater improvement in distress (P=0.020) with a trend toward improvement in the ejaculatory control domain scores (P=0.093). The responder analysis showed a statistically significant response to the use of benzocaine versus placebo, attesting an IELT increase that was clinically meaningful. Benzocaine wipes were well tolerated by subjects and partners.

Conclusion

This randomized, placebo controlled clinical trial with crossover design showed that benzocaine wipes applied topically to the penis prior to sexual intercourse had a statistically significant prolongation of time to ejaculation, a clinically meaningful benefit, in the treatment of premature ejaculation. Furthermore, benzocaine wipes were well tolerated by the subjects and no evidence of transference to their female partners.

Keywords
premature ejaculation
benzocaine
PREBOOST
placebo-controlled
wipes
sexual satisfaction
Share
Back to top